Cargando…

Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota

Chronic kidney disease (CKD) is a global epidemic with an increasing prevalence worldwide. Effective preventive strategies are urgently needed. This study aimed to investigate the effect of nutraceutical components, a fermented soybean product (ImmuBalance, IMB) and an oligo-lactic acid product (LAP...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Li-Xia, Abdolmaleky, Hamid M., Yin, Sheng, Wang, Yihong, Zhou, Jin-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468970/
https://www.ncbi.nlm.nih.gov/pubmed/32784477
http://dx.doi.org/10.3390/nu12082376
_version_ 1783578327023353856
author He, Li-Xia
Abdolmaleky, Hamid M.
Yin, Sheng
Wang, Yihong
Zhou, Jin-Rong
author_facet He, Li-Xia
Abdolmaleky, Hamid M.
Yin, Sheng
Wang, Yihong
Zhou, Jin-Rong
author_sort He, Li-Xia
collection PubMed
description Chronic kidney disease (CKD) is a global epidemic with an increasing prevalence worldwide. Effective preventive strategies are urgently needed. This study aimed to investigate the effect of nutraceutical components, a fermented soybean product (ImmuBalance, IMB) and an oligo-lactic acid product (LAP), on the prevention of adenine-induced CKD in mice. Female C57BL/6 mice were randomly assigned into following experimental groups: negative control; model control; and models treated with IMB at 250 or 1000 mg/kg body weight (BW), LAP at 1000 or 2000 mg/kg BW, and IMB/LAP combinations. The CKD model was established by intraperitoneal injection of adenine daily for 4 weeks, and treatments started 2 weeks before adenine injection and ended after 10 weeks. Compared with the model control, the treatments did not significantly alter the body weight or food intake. Both IMB and LAP, especially their combination, significantly inhibited tubular dilation, tubulointerstitial degeneration or atrophy, interstitial chronic inflammation and acute inflammation in the kidneys of CKD mice, and significantly decreased serum cystatin C levels. IMB or LAP significantly reversed CKD-associated increases of circulating and kidney levels of inflammatory cytokines, circulating levels of kidney injury biomarkers, and kidney levels of stem cell biomarkers, and significantly reversed CKD-associated reduction of cecum Clostridium leptum group. Our results suggest that dietary supplementation of IMB or LAP may significantly delay the development and/or progression of CKD.
format Online
Article
Text
id pubmed-7468970
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74689702020-09-04 Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota He, Li-Xia Abdolmaleky, Hamid M. Yin, Sheng Wang, Yihong Zhou, Jin-Rong Nutrients Article Chronic kidney disease (CKD) is a global epidemic with an increasing prevalence worldwide. Effective preventive strategies are urgently needed. This study aimed to investigate the effect of nutraceutical components, a fermented soybean product (ImmuBalance, IMB) and an oligo-lactic acid product (LAP), on the prevention of adenine-induced CKD in mice. Female C57BL/6 mice were randomly assigned into following experimental groups: negative control; model control; and models treated with IMB at 250 or 1000 mg/kg body weight (BW), LAP at 1000 or 2000 mg/kg BW, and IMB/LAP combinations. The CKD model was established by intraperitoneal injection of adenine daily for 4 weeks, and treatments started 2 weeks before adenine injection and ended after 10 weeks. Compared with the model control, the treatments did not significantly alter the body weight or food intake. Both IMB and LAP, especially their combination, significantly inhibited tubular dilation, tubulointerstitial degeneration or atrophy, interstitial chronic inflammation and acute inflammation in the kidneys of CKD mice, and significantly decreased serum cystatin C levels. IMB or LAP significantly reversed CKD-associated increases of circulating and kidney levels of inflammatory cytokines, circulating levels of kidney injury biomarkers, and kidney levels of stem cell biomarkers, and significantly reversed CKD-associated reduction of cecum Clostridium leptum group. Our results suggest that dietary supplementation of IMB or LAP may significantly delay the development and/or progression of CKD. MDPI 2020-08-08 /pmc/articles/PMC7468970/ /pubmed/32784477 http://dx.doi.org/10.3390/nu12082376 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
He, Li-Xia
Abdolmaleky, Hamid M.
Yin, Sheng
Wang, Yihong
Zhou, Jin-Rong
Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota
title Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota
title_full Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota
title_fullStr Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota
title_full_unstemmed Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota
title_short Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota
title_sort dietary fermented soy extract and oligo-lactic acid alleviate chronic kidney disease in mice via inhibition of inflammation and modulation of gut microbiota
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468970/
https://www.ncbi.nlm.nih.gov/pubmed/32784477
http://dx.doi.org/10.3390/nu12082376
work_keys_str_mv AT helixia dietaryfermentedsoyextractandoligolacticacidalleviatechronickidneydiseaseinmiceviainhibitionofinflammationandmodulationofgutmicrobiota
AT abdolmalekyhamidm dietaryfermentedsoyextractandoligolacticacidalleviatechronickidneydiseaseinmiceviainhibitionofinflammationandmodulationofgutmicrobiota
AT yinsheng dietaryfermentedsoyextractandoligolacticacidalleviatechronickidneydiseaseinmiceviainhibitionofinflammationandmodulationofgutmicrobiota
AT wangyihong dietaryfermentedsoyextractandoligolacticacidalleviatechronickidneydiseaseinmiceviainhibitionofinflammationandmodulationofgutmicrobiota
AT zhoujinrong dietaryfermentedsoyextractandoligolacticacidalleviatechronickidneydiseaseinmiceviainhibitionofinflammationandmodulationofgutmicrobiota